PCSK9 and stroke disorder: In addition to alirocumab and evolocumab for cholesterol-lowering and evolocumab for the prevention of heart attack and stroke, which are the only two approved inhibitors of PCSK9, bococizumab is another monoclonal antibody against PCSK9 [98,99].